Journal
JOURNAL OF NEUROLOGY
Volume 251, Issue 9, Pages 1080-1084Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-004-0481-5
Keywords
amyotrophic lateral sclerosis; motor neuron disease; rasagiline; G93A animals; experimental therapeutics
Categories
Ask authors/readers for more resources
Rasagiline is an antiapoptotic compound with neuroprotective potential. We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS). Endpoints of experimental treatment were survival and motor activity. The drug had a significant dose-dependent therapeutic effect on both preclinical and clinical motor function and survival of the animals. We also found that the combination of rasagiline with riluzole is safe and increases survival by about 20% in a dose-dependent manner. Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available